Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan B. Sandler, Robert J. Gray, Michael C. Perry, Julie Renee Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson
New England Journal of Medicine · 2006 · 5,796 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Sandler, A. B., Gray, R. J., Perry, M. C., Brahmer, J. R., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006). Paclitaxel–Carboplatin alone or with bevacizumab for Non–Small-Cell lung cancer. New England Journal of Medicine, 355(24), 2542–2550. https://doi.org/10.1056/nejmoa061884
In text: (Sandler et al., 2006)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. METHODS: Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival. RESULTS: The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. CONCLUSIONS: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)
Related papers
Metadata from OpenAlex (CC0). Citations are generated from the published record.